Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Gains from Sales and Divestitures (2018 - 2025)

Historic Gains from Sales and Divestitures for Nephros (NEPH) over the last 8 years, with Q3 2025 value amounting to $160843.0.

  • Nephros' Gains from Sales and Divestitures changed N/A to $160843.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $160843.0, marking a year-over-year change of. This contributed to the annual value of $42167.0 for FY2024, which is 7751.13% down from last year.
  • As of Q3 2025, Nephros' Gains from Sales and Divestitures stood at $160843.0.
  • In the past 5 years, Nephros' Gains from Sales and Divestitures ranged from a high of $187503.0 in Q4 2023 and a low of $23781.0 during Q4 2021
  • For the 5-year period, Nephros' Gains from Sales and Divestitures averaged around $94871.6, with its median value being $58961.0 (2025).
  • In the last 5 years, Nephros' Gains from Sales and Divestitures tumbled by 9995.68% in 2021 and then surged by 31916.97% in 2023.
  • Over the past 5 years, Nephros' Gains from Sales and Divestitures (Quarter) stood at $23781.0 in 2021, then surged by 88.1% to $44732.0 in 2022, then skyrocketed by 319.17% to $187503.0 in 2023, then crashed by 77.51% to $42167.0 in 2024, then soared by 281.44% to $160843.0 in 2025.
  • Its Gains from Sales and Divestitures was $160843.0 in Q3 2025, compared to $146114.0 in Q2 2025 and $58961.0 in Q1 2025.